Alpha-synucleinum

E Vicipaedia
Jump to navigation Jump to search
Esculaap4.svg
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.
Synucleinum alpha
Alia nomina SNCA, NACP, PARK1, PARK4, PD1
Synucleinum alpha
Fontes externae OMIM: 163890
Locus geni (homo)
Chromosomate 4 locatum
Chromosoma 4 (humanum)

Alpha-synucleinum (sive, raro, NACP) est unum ex tribus proteinis familiae synucleinorum. Ut omnia synucleina alpha-synucleinum adhuc solum in vertebratis inventum est, tunc in cerebrorum synapsibus praesynapticis[1]. Adhuc quaedam functio certo nota non est. Anticorpus contra alpha-synucleinum in morbo Parkinson tractando investigatur.

Sicubi in cerebro accidat, ut laesiones cerebrales alpha-synucleinis glomeratis sibi forment, ut in variis morbis neurodegenerativis, ii gregi synucleopathiarum supponuntur[2].

Nomen geni sui dicitur SCNA. Mutationes geni geneticae cum morbo Parkinson sociatae sunt.

Synucleina[recensere | fontem recensere]

Synucleina sunt proteina parva, solubilia et praecipue in tela nervosa et certis tumoribus inventa. In organismo humano tres familiae descripta sunt: alpha, beta, gamma[3]. Alpha-synucleina nexus cum morbo Parkinson et aliis morbis neurodegenerativis ostendunt. Beta-synucleina autem quasi alpha-synucleinis antagonistae videbatur. Gamma-synucleinum in certis tumoribus, in oculorum morbis inventum est. Adhuc synucleina in vertebratis descripta sunt[4].

Genetica alpha-synucleini[recensere | fontem recensere]

Genum alpha-synucleini SCNA vocatur et humano in chromosomate 4 locatum est (4q22.1)[5]. Geno SNCA longitudinis 146[6] kilobasium (kb) sex exona sunt ex quibus quinque proteino scribunt[7].

Significatio pathologica[recensere | fontem recensere]

Morborum neurodegenerativorum cum corpusculis Leweyanis, ut morbus Parkinson vel dementia cum corpusculis Leweyanis, cursus vagior ostendit. Multitudo autem alpha-synucleini aggregati, per haec amyloidum formans, in cerebro et dementiae initium velut cursus morbi indicat[8]. Nuper aggregationem pathologicam in drosophila melanogastro per monomerum AS69 inhiberi posse demonstratum est[9].

Anticorpus contra alpha-synucleinum[recensere | fontem recensere]

Conatus et experimentum est therapia morbi Parkinson cum anticorporibus contra alpha-synucleinum[10]. Effectus anticorpus monoclonalis PRX002 (Prasinezumabum)/RG7935 nunc investigatur[11].

Notae[recensere | fontem recensere]

  1. Jakes R, Spillantini MG, Goedert M (1994). "Identification of two distinct synucleins from human brain". FEBS Lett 345 (1): 27-32 
  2. Giasson BI, Duda JE, Murray IV, Chen Q, Souza JM, Hurtig HI, Ischiropoulos H, Trojanowski JQ, Lee VM (2000). "Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions". Science 290 (5493): 985-9 
  3. Surguchov A (2008). "Molecular and cellular biology of synucleins". Int Rev Cell Mol Biol 270: 225-317 
  4. Surguchov A (2015). "Intracellular Dynamics of Synucleins: "Here, There and Everywhere"". Int Rev Cell Mol Biol 320: 103-69 
  5. Chen X., de Silva H. A., Pettenati M. J., Rao P. N., St George-Hyslop P., Roses A. D., Xia Y., Horsburgh K., Ueda K., Saitoh T. (1995). "The human NACP/alpha-synuclein gene: chromosome assignment to 4q21.3-q22 and TaqI RFLP Analysis". Genomics 26: 425-7 
  6. mus: 118 kb
  7. Touchman J. W., Dehejia A., Chiba-Falek O., Cabin D. E., Schwartz J. R., Orrison B. M., Polymeropoulos M. H., Nussbaum R. L. (2001). "Human and mouse alpha-synuclein genes: comparative genomic sequence analysis and identification of a novel gene regulatory element". Genome research 11 (1): 78-86 
  8. Irwin DJ, Grossman M, Weintraub D, Hurtig HI, Duda JE, Xie SX, Lee EB, Van Deerlin VM, Lopez OL, Kofler JK, Nelson PT, Jicha GA, Woltjer R, Quinn JF, Kaye J, Leverenz JB, Tsuang D, Longfellow K, Yearout D, Kukull W, Keene CD, Montine TJ, Zabetian CP, Trojanowski JQ (2017). "Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis". Lancet Neurol 16(1): 55-65 
  9. Agerschou E. D., Flagmeier P., Saridaki T., Galvagnion C., Komnig D., Heid L., Prasad V., Shaykhalishahi H., et al. (Aug 2019). "An engineered monomer binding-protein for α-synuclein efficiently inhibits the proliferation of amyloid fibrils". Elife (8): e46112 
  10. Jankovic J., Goodman I., Safirstein B., Marmon T. K., Schenk D. B., Koller M., Zago W., Ness D. K., Griffith S. G., Grundman M., Soto J., Ostrowitzki S., Boess F. G., Martin-Facklam M., Quinn J. F., Isaacson S. H., Omidvar O., Ellenbogen A., Kinney G. G. (2018). "Safety and Tolerability of Multiple Ascending Doses of PRX002/RG7935, an Anti-α-Synuclein Monoclonal Antibody, in Patients With Parkinson Disease: A Randomized Clinical Trial". JAMA Neurol: doi: 10.1001/jamaneurol.2018.1487 
  11. Cuius investigatio PASADENA nominata est.

Nexus interni

imago adenomatis serratae coloni Haec stipula ad pathologiam spectat. Amplifica, si potes!